A systematic review by Tejedor-Alonso and colleagues found the use of BB and ACE-I therapies increased the severity of reactions, while a retrospective cohort study by White et al. demonstrated that BB use may not have a clinically significant impact on epinephrine dosing among ED patients with anaphylaxis [5,6]. This evidence concerns the gene ACE and anaphylaxis.